Combining savolitinib with osimertinib can reverse osimertinib resistance in patients with advanced, EGFR-mutant NSCLC, data suggest.

The following is a summary of "Eplerenone, diabetes, and chronic kidney disease in patients hospitalized for acute heart ...

The companion diagnostic (CDx) for EGFR exon 20 insertion mutation (exon20ins) for sunvozertinib, developed through the collaboration of Burning Rock and Dizal, has been approved by the National ...

Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focused on the application of next generation sequencing (NGS) ...

For patients given osimertinib, the median OS was 36.7 months (95% CI, 33.4-41.0), which was consistent with prior studies evaluating osimertinib. Popat S, Reckamp KL, Califano R, et al. Amivantamab ...

In the osimertinib group, the median OS was 36.7 months (95% CI, 33.4-41.0), which was consistent with prior ... 1074 patients with locally advanced or metastatic NSCLC with EGFR ex19del or ...

safe and convenient treatment for patients with EGFR-mutated lung cancer across stages and lines of treatment." Susan Galbraith, Executive Vice President, Oncology Hematology R&D, AstraZeneca ...

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, will present a deep learning study on Epidermal Growth Factor Receptor (EGFR) mutation ...

RYBREVANT plus LAZCLUZE is approved in the United States, Europe and other markets around the world for patients with first-line EGFR-mutated NSCLC. These OS results will be shared with health ...

In patients with type 2 diabetes and albuminuria, dapagliflozin leads to a significant reduction in urine ...

Elon Musk said Friday his artificial intelligence startup, xAI, has acquired his social media platform, X, for $33 billion in an all-stock transaction. Musk announced the deal in a Friday post ...